2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.19 The Effect of COVID-19 On Treatment Outcomes in Non-Small Cell Lung Cancer Patients: A Propensity Score Matched Analysis

P4.11E.19 The Effect of COVID-19 On Treatment Outcomes in Non-Small Cell Lung Cancer Patients: A Propensity Score Matched Analysis

Back to course

Pdf Summary

The study, conducted by researchers from several health institutions, investigates the impact of COVID-19 on treatment outcomes for patients with non-small cell lung cancer (NSCLC). Utilizing the TriNetX database of 60 healthcare organizations, the study employs a propensity-matched retrospective cohort design. Patients diagnosed with NSCLC after January 1, 2019, were matched based on stage, age, race, gender, and comorbidities to compare those with COVID-19 (553 patients) to those without (3025 patients).<br /><br />Surprisingly, the results indicate no significant differences in survival or treatment-related adverse events between COVID-19 positive and negative cohorts. Specifically, the overall survival rate for COVID-19 negative patients was 69.2% against a 65.6% survival rate for COVID-19 positive patients. The relative risk (RR) for 1-year mortality was 0.897 (p = 0.22), and for 3-year mortality was 1.11 (p = 0.13), indicating no statistical significance. Similarly, the risk for treatment-related adverse effects over one and three years displayed no significant difference, with RR of 1.09 (p = 0.42) and 1.16 (p = 0.15) respectively.<br /><br />Contrary to initial concerns, COVID-19-induced inflammation did not worsen cancer prognoses or increase treatment-associated risks in NSCLC patients, suggesting resilience in cancer treatment during the pandemic. The findings underscore the robustness of current treatment regimens despite COVID-19 challenges. Furthermore, the study notes that while the widespread implementation of COVID-19 vaccines is likely reducing virus-related mortality, its specific influence on cancer treatment outcomes still warrants further investigation. Overall, the study concludes that COVID-19 does not significantly alter survival or treatment outcomes in NSCLC patients.

Asset Subtitle

Wint Yan Aung

Meta Tag

Speaker Wint Yan Aung

Topic Metastatic NSCLC – Immunotherapy

Keywords

COVID-19

NSCLC

lung cancer

treatment outcomes

survival rate

TriNetX database

propensity-matched

retrospective cohort

adverse events

cancer prognoses